Baidu
map

JCEM:2型糖尿病发生发展的因果关联

2018-12-20 xing.T MedSci原创

由此可见,BMI、葡萄糖水平、HOMA2-IR和HOMA2-β与T2D之间存在因果关系。

研究人员观察到肥胖、葡萄糖、胰岛素抵抗(HOMA2-IR)和胰岛素分泌(HOMA2-β)与2型糖尿病(T2D)相关。然而,每个参数对这种风险的因果遗传贡献在很大程度上是未知的,但是对研究来说很重要,因为观察数据容易产生混淆,而遗传因果数据没有混淆和反向因果关系。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员评估了哥本哈根一般人群研究中95540名受试者体重指数(BMI)、葡萄糖水平、C肽水平、HOMA2-IR和HOMA2-β对T2D风险的因果遗传贡献,并估计了绝对的10年风险。

研究人员进行了Cox回归分析、工具变量分析和泊松回归分析以估计观察风险比、因果、遗传比值比和T2D的绝对10年风险。

对于每个指标水平增加1个标准差,BMI与T2D的观察性风险增加66%(62%-72%)以及因果遗传性风险增加121%(25%-291%)相关;葡萄糖与T2D的观察性风险增加44%(41%-46%)以及因果遗传性风险增加183%(56%-416%)有关;而HOMA2-IR与T2D的观察性风险增加30%(18%-44%)以及因果遗传性风险增加12%(2%-22%)相关。相反,对于以下指标每增加1个标准差的水平,HOMA2-β与T2D的观察性风险降低14%(11%-16%)以及因果遗传性风险降低21%(8%-32%)相关。HOMA2-IR的上三分位数与肥胖女性和男性的绝对10年糖尿病风险相关,分别为31%和37%,并且这些患者年龄大于60岁,葡萄糖水平在6.1-11.0 mmol/L之间。

由此可见,BMI、葡萄糖水平、HOMA2-IR和HOMA2-β与T2D之间存在因果关系。

原始出处:

Sarah C W Marott,et al.Causal associations in type 2 diabetes development.J Clin Endocrinol Metab. 2018. https://doi.org/10.1210/jc.2018-01648

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063223, encodeId=e41a20632238b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 22 17:37:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030745, encodeId=38402030e4564, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Nov 14 14:37:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777841, encodeId=c90a1e77841e0, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Feb 04 10:37:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042126, encodeId=e8df1042126f6, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 21 00:37:00 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2018-12-22 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063223, encodeId=e41a20632238b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 22 17:37:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030745, encodeId=38402030e4564, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Nov 14 14:37:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777841, encodeId=c90a1e77841e0, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Feb 04 10:37:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042126, encodeId=e8df1042126f6, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 21 00:37:00 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063223, encodeId=e41a20632238b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 22 17:37:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030745, encodeId=38402030e4564, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Nov 14 14:37:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777841, encodeId=c90a1e77841e0, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Feb 04 10:37:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042126, encodeId=e8df1042126f6, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 21 00:37:00 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2019-02-04 smallant2015
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063223, encodeId=e41a20632238b, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Dec 22 17:37:00 CST 2018, time=2018-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030745, encodeId=38402030e4564, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Thu Nov 14 14:37:00 CST 2019, time=2019-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777841, encodeId=c90a1e77841e0, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Mon Feb 04 10:37:00 CST 2019, time=2019-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042126, encodeId=e8df1042126f6, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Fri Dec 21 00:37:00 CST 2018, time=2018-12-21, status=1, ipAttribution=)]
    2018-12-21 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Diabetes Obes Metab:长效胰岛素对1型和2型糖尿病患者的疗效和危害比较

在接受德谷胰岛素、地特胰岛素和甘精胰岛素治疗的患者之间没有观察到血糖控制的差异。 德谷胰岛素与甘精胰岛素相比,低血糖的可能性较小,服用地特胰岛素的患者体重低于使用德谷胰岛素或甘精胰岛素的患者。在2型糖尿病中,地特胰岛素比甘精胰岛素更可能因不良事件而停药。

2018《中国老年2型糖尿病诊疗措施专家共识》解读

导读:我国老年人绝大多数已无工作压力,对于糖尿病的治疗依从性高于中青年患者[1],因此提高全民健康意识,提高患者的自我管理能力,可以明显改善老年糖尿病患者的治疗状况。中国老年医学学会特制定了《中国老年2型糖尿病诊疗措施专家共识(2018年版)》[1],以进一步提高老年糖尿病管理水平。本文就该共识中合理应用降糖药的内容进行解读。疾病阶段和血糖水平决定用药降糖药的选用主要考虑两点,患者所处的疾病发展阶

Obesity:肥胖合并2型糖尿病心血管风险更高怎么破?又一帮手来助力

合并肥胖的2型糖尿病(T2DM)患者其非酒精性脂肪肝(NAFLD)易感性更高,根据Obesity上发表的一项研究显示,pegbelfermin——聚乙二醇修饰的重组人成纤维细胞生长因子21类似物治疗12周,可改善肥胖T2DM患者的血脂谱。

CDS2018| 高肾糖阈与T2DM心血管危险因素相关,并可能成为指导糖尿病精准治疗的指标

在刚刚结束的中华医学会糖尿病学分会第二十二次全国学术会议(CDS2018)上,北京大学人民医院纪立农教授和韩学尧教授所带领的研究团队发表的研究“2型糖尿病肾性糖尿的临床和遗传特征”获得了2017年度中国糖尿病十大研究奖。课题组根据研究结果首次提出了高肾糖阈是2型糖尿病(T2DM)心血管并发症危险因素的科学假设。

Hypertension:2型糖尿病患者血压与心血管疾病的关系

由此可见,2型糖尿病患者CVD风险较低的最佳临界值可能是SBP为130mmHg或舒张压为80mmHg。

美国心脏病学会发表共识,所有2型糖尿病患者都应该做这件事

China PEACE研究新分析,我国半数心梗患者1年内未重返工作 中国心脏康复工作不到位 重返工作是判断急性心肌梗死(AMI)患者恢复情况的重要指标。近日,北京大学人民医院陈红教授团队采用China PEACE研究数据分析发现,我国近一半AMI住院患者在12个月内没有重返工作岗位。(JAMA Netw Open. 2018;1:e184831)

Baidu
map
Baidu
map
Baidu
map